International Journal of Rheumatology / 2017 / Article / Tab 3

Review Article

Tofacitinib versus Biologic Treatments in Moderate-to-Severe Rheumatoid Arthritis Patients Who Have Had an Inadequate Response to Nonbiologic DMARDs: Systematic Literature Review and Network Meta-Analysis

Table 3

Results for MTX combination therapy as obtained with random-effects network meta-analysis at 24 weeks: TOF 5 mg BID + MTX and TOF 10 mg BID + MTX versus treatment.

Treatment (+ MTX)ACR20
OR (95% CI)
ACR50
OR (95% CI)
ACR70
OR (95% CI)
Withdrawals due to AEs
OR (95% CI)
ACR20
OR (95% CI)
ACR50
OR (95% CI)
ACR70
OR (95% CI)
Withdrawals due to AEs
OR (95% CI)
TOF 5 mg BID + MTX versus other treatments TOF 10 mg BID + MTX versus other treatments

TOF 5 mg BIDNANANANA1.31 (0.57, 3.02)1.25 (0.59, 2.65)1.32 (0.74, 2.21)0.79 (0.41, 1.70)
TOF 10 mg BID0.76 (0.33, 1.76)0.80 (0.38, 1.71)0.76 (0.45, 1.36)1.26 (0.59, 2.46)NANANANA
GLB 50 mg Q4W0.81 (0.15, 4.42)1.00 (0.26, 3.64)1.32 (0.32, 4.98)2.84 (0.63, 13.21)1.07 (0.20, 5.74)1.26 (0.33, 4.54)1.73 (0.41, 6.43)2.25 (0.51, 10.87)
TCZ 8 mg/kg Q4W0.86 (0.24, 3.07)0.89 (0.27, 2.87)0.71 (0.24, 1.91)0.86 (0.30, 2.47)1.12 (0.31, 4.04)1.11 (0.33, 3.60)0.93 (0.31, 2.49)0.68 (0.24, 2.09)
CZP 400 mg Q4W1.08 (0.20, 5.73)1.27 (0.23, 6.65)53.28 (2.66, +infty)1.68 (0.31, 8.22)1.42 (0.26, 7.47)1.60 (0.29, 8.32)70.27 (3.49, +infty)1.35 (0.25, 6.79)
IFX 3 mg/kg Q8W1.48 (0.41, 5.22)1.58 (0.39, 6.53)1.46 (0.47, 4.31)0.94 (0.27, 3.14)1.94 (0.54, 6.85)1.99 (0.48, 8.03)1.92 (0.59, 5.51)0.75 (0.21, 2.58)
ABT 125 mg QW1.04 (0.27, 3.94)0.97 (0.28, 3.21)1.43 (0.52, 3.31)2.62 (0.83, 8.59)1.36 (0.35, 5.15)1.22 (0.35, 4.01)1.88 (0.66, 4.27)2.08 (0.68, 7.22)
ABT 10 mg/kg Q4W1.50 (0.50, 4.44)1.17 (0.42, 3.26)1.59 (0.64, 3.50)1.83 (0.65, 5.15)1.96 (0.65, 5.80)1.47 (0.52, 4.04)2.10 (0.68, 5.84)1.45 (0.53, 4.30)
ETN 50 mg QW1.49 (0.40, 5.39)1.56 (0.47, 5.18)1.53 (0.56, 3.99)2.99 (0.45, 17.55)1.95 (0.53, 7.01)1.96 (0.59, 6.41)2.02 (0.72, 5.11)2.38 (0.37, 14.70)
ETN 25 mg BIW1.08 (0.27, 1.95)1.24 (0.30, 4.11)1.75 (0.54, 4.50)2.37 (0.59, 7.31)1.41 (0.35, 5.31)1.55 (0.37, 5.12)2.31 (0.68, 5.84)1.88 (0.50, 6.08)
ADA 40 mg Q2W0.74 (0.27, 1.95)0.87 (0.35, 2.03)1.46 (0.66, 2.76)1.31 (0.56, 3.23)0.97 (0.35, 2.55)1.09 (0.44, 2.54)1.92 (0.84, 3.60)1.04 (0.46, 2.75)
PLBO3.15 (1.39, 7.05)4.55 (2.11, 9.66)6.19 (3.15, 12.04)1.89 (0.86, 3.87)4.11 (1.82, 9.26)5.68 (2.65, 11.98)8.16 (4.04, 15.65)1.51 (0.71, 3.28)

Comparable;  more effective.
OR > 1 favors TOF 5 mg; OR < 1 favors TOF 5 mg; OR > 1 favors TOF 10 mg; OR < 1 favors TOF 10 mg.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.